Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Bio-Techne (TECH) Short-Term Debt repayments (2016 - 2026)

Bio-Techne has reported Short-Term Debt repayments over the past 12 years, most recently at $40.0 million for Q4 2025.

  • For Q4 2025, Short-Term Debt repayments changed N/A year-over-year to $40.0 million; the TTM value through Dec 2025 reached $144.0 million, down 2.04%, while the annual FY2025 figure was $77.0 million, 69.92% down from the prior year.
  • Short-Term Debt repayments for Q4 2025 was $40.0 million at Bio-Techne, down from $46.0 million in the prior quarter.
  • Over five years, Short-Term Debt repayments peaked at $441.0 million in Q3 2022 and troughed at $3.1 million in Q2 2022.
  • A 5-year average of $70.4 million and a median of $54.6 million in 2021 define the central range for Short-Term Debt repayments.
  • On a YoY basis, Short-Term Debt repayments climbed as much as 762.59% in 2022 and fell as far as 97.6% in 2022.
  • Year by year, Short-Term Debt repayments stood at $58.1 million in 2021, then rose by 11.24% to $64.7 million in 2022, then fell by 10.3% to $58.0 million in 2023, then tumbled by 67.24% to $19.0 million in 2024, then soared by 110.53% to $40.0 million in 2025.
  • Business Quant data shows Short-Term Debt repayments for TECH at $40.0 million in Q4 2025, $46.0 million in Q3 2025, and $50.0 million in Q2 2025.